StockNews.com Lowers Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell

Posted by on Apr 11th, 2023

StockNews.com downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) from a hold rating to a sell rating in a research note released on Monday morning.

A number of other research firms also recently commented on ORMP. Cantor Fitzgerald downgraded Oramed Pharmaceuticals from an overweight rating to a neutral rating in a report on Friday, January 13th. Canaccord Genuity Group lowered shares of Oramed Pharmaceuticals from a buy rating to a hold rating and decreased their price target for the company from $30.00 to $3.00 in a report on Thursday, January 12th. Finally, HC Wainwright cut shares of Oramed Pharmaceuticals from a buy rating to a neutral rating in a report on Tuesday, January 17th.

Oramed Pharmaceuticals Price Performance

Shares of ORMP stock opened at $2.15 on Monday. The firm has a fifty day moving average of $2.13 and a two-hundred day moving average of $5.45. The firm has a market cap of $85.53 million, a P/E ratio of -2.29 and a beta of 1.81. Oramed Pharmaceuticals has a 1-year low of $1.81 and a 1-year high of $13.73.

Insider Activity at Oramed Pharmaceuticals

In related news, Director Yadin Rozov bought 20,000 shares of the stock in a transaction on Monday, March 13th. The shares were purchased at an average price of $1.96 per share, with a total value of $39,200.00. Following the purchase, the director now owns 36,500 shares in the company, valued at $71,540. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Oramed Pharmaceuticals news, CEO Nadav Kidron purchased 100,000 shares of the company’s stock in a transaction on Tuesday, March 14th. The shares were purchased at an average cost of $2.01 per share, for a total transaction of $201,000.00. Following the completion of the transaction, the chief executive officer now owns 100,000 shares in the company, valued at $201,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Yadin Rozov acquired 20,000 shares of Oramed Pharmaceuticals stock in a transaction dated Monday, March 13th. The shares were acquired at an average price of $1.96 per share, with a total value of $39,200.00. Following the transaction, the director now owns 36,500 shares in the company, valued at approximately $71,540. The disclosure for this purchase can be found here. Insiders have purchased a total of 146,000 shares of company stock worth $293,240 over the last ninety days. 6.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Oramed Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Altshuler Shaham Ltd acquired a new position in Oramed Pharmaceuticals in the fourth quarter worth approximately $153,000. 683 Capital Management LLC acquired a new position in shares of Oramed Pharmaceuticals in the 4th quarter worth $247,000. Marshall Wace LLP boosted its position in shares of Oramed Pharmaceuticals by 31.6% in the 4th quarter. Marshall Wace LLP now owns 37,399 shares of the biotechnology company’s stock valued at $450,000 after purchasing an additional 8,990 shares during the period. Wells Fargo & Company MN increased its stake in Oramed Pharmaceuticals by 9.0% in the 4th quarter. Wells Fargo & Company MN now owns 64,682 shares of the biotechnology company’s stock worth $778,000 after purchasing an additional 5,350 shares in the last quarter. Finally, Barclays PLC raised its holdings in Oramed Pharmaceuticals by 84.6% during the 4th quarter. Barclays PLC now owns 39,778 shares of the biotechnology company’s stock worth $478,000 after buying an additional 18,235 shares during the period. 10.08% of the stock is currently owned by institutional investors.

About Oramed Pharmaceuticals

(Get Rating)

Oramed Pharmaceuticals, Inc engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.

Featured Articles

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.